PSIL
AdvisorShares Psychedelics ETF
PSIL is actively managed to provide exposure to the emerging global psychedelics industry.
International
EQUITY
Active
MANAGEMENT STYLE
$ 41.7 M
ASSETS UNDER MGMT
99 bp
EXPENSES
Fund Basics
| Inception date | Sep 15, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| COMPASS PATHWAYS PLC ADR | 12.0 % |
| ATAIBECKLEY INC | 9.6 % |
| DEFINIUM THERAPEUTICS INC | 8.8 % |
| RELMADA THERAPEUTICS INC | 7.8 % |
| NRX PHARMACEUTICALS INC ORDINARY SHARES | 7.1 % |
| GH RESEARCH PLC | 5.0 % |
| ALKERMES PLC | 4.5 % |
| NEUROCRINE BIOSCIENCES INC | 4.3 % |
| ALTO NEUROSCIENCE INC | 4.2 % |
| HELUS PHARMA INC ORDINARY SHARES | 4.0 % |
Constituent Breakdown
| Number of holdings | 33 |
| Herfindahl-Hirschman Index | 599 |
| Wgt avg mkt cap (mns) | $36,872 |
| Large cap (>$10bn) | 11.9% |
| Mid cap ($2-10bn) | 16.6% |
| Small cap (<$2bn) | 15.1% |
| Developed mkts. | 47.7% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 42.4 % |
 |
IRELAND | 4.5 % |
 |
CANADA | 0.8 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 40.1% | 73.6% | 56.9% | 9.0% | -- | -- | -- | -25.7% |
| Dividend Yield | 0.0% | 17.5% | 10.4% | 4.9% | -- | -- | -- | 2.4% |
| Total Returns | 40.1% | 91.1% | 67.3% | 13.9% | -- | -- | -- | -23.3% | Ann. Volatility | 42.5% | 41.0% | 83.4% | 71.7% | -- | -- | -- | 63.0% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.42 | 18% |
| MSCI EAFE | 0.99 | 14% |
| MSCI Emg Mkts | 0.57 | 10% |
Liquidity Measures
| Avg. volume (000) | 61 |
| ADV traded (mns) | $1 |
| Turnover | 3.5% |
| Avg. Bid/Ask (% of price) | 0.51% |
Technical Indicators
| 30d moving avg. (EMA) | $22.47 |
| Relative strength (RSI) | 61 |
| MACD/Signal | 0.83/0.82 |
| Bollinger Bands (Upper/Lower) | $25.34/$20.84 |
| Short interest (% of AUM) | 7.6% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PSIL |
Expenses vs. PSIL |
ALTAR Score™ vs. PSIL |
|---|---|---|---|---|
| IBRN | iShares Neuroscience and Healthcare ETF | 13.4% | -52 bp | +1.4% |
| MEDX | Horizon Kinetics Medical ETF | 12.1% | -14 bp | +2.9% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 10.7% | -39 bp | +8.4% |
| PJP | Invesco Pharmaceuticals ETF | 10.2% | -42 bp | +8.8% |
Risk and Returns: PSIL vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/21/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.4%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 417 funds in the International Equity category with an average
ALTAR Score™ of 6.6% and a standard deviation
of 1.8%. PSIL's ALTAR Score™ is approximately -4.5 standard
deviations above the category average. This places PSIL in the 1st percentile
among funds in the category.
Sell-Side Consensus
$26.07
PRICE TARGET
+8.1%
UPSIDE
Bid/Ask Spreads
51 bp
AVG SPREAD
20 —
102 bp
RANGE